KALV | Ticker Profile - Titan Protect

KALV

KalVista Pharmaceuticals, Inc.

Healthcare · Biotechnology · NGM

$26.95

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 57.1%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.4B

Total market value of the company

Trailing P/E

N/A

Forward P/E

22.39

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

-118.7%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$27.00

+0% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 5 analysts covering this stock

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.

https://www.kalvista.com

Country: United States Employees: 275 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.974

Good returns relative to risk taken

Kelly Fraction

0.0757

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.066

Returns exceed worst-case losses — strong risk profile

Annual Return

55.4%

Historical annualised return based on price data

Max Drawdown

-51.9%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.12

Very low correlation to market moves

52W High

$26.85

-0% below the year high

52W Low

$9.83

174% above the year low

Avg Volume

3,365,522

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

25.3%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.94

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

5.17

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.97

Like current ratio but excludes inventory — stricter test

Gross Margin

51.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-57.4%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$114M

Total revenue over the last 12 months

Net Income

$-135,936,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$35.00

Target Median

$27.00

Target Low

$27.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go